Leukemia Clinical Trial
Official title:
A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)
Verified date | August 2018 |
Source | Il-Yang Pharm. Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic
myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase
inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of
CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated
phases.
Phase 1
1. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of
oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who
are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to
at least one second-generation targeted anticancer agent while being resistant, suboptimal
responsive, or intolerant to imatinib simultaneously.
Phase 2
1. To investigate safety of oral Radotinib HCl in CML patients who are resistant or
intolerable to imatinib in the chronic and accelerated phases.
2. To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients
who are resistant or intolerable to imatinib in the chronic and accelerated phases.
Status | Completed |
Enrollment | 85 |
Est. completion date | July 13, 2018 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Phase I 1. Age = 18 years old 2. Ph+ CML patients who are resistant at chronic, accelerate, and acute phase, or suboptimal responsive, or intolerant to imatinib or resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously. 3. WHO Performance status of =2 4. Patients must have the following laboratory values With normal liver and renal function 5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug. Phase II 1. Age = 18 years old 2. Ph+ CML patients in chronic or accelerated phase who are resistant or intolerant to Imatinib mesylate 3. WHO Performance status of =2 4. Patients must have the following laboratory values With normal liver and renal function 5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug. Exclusion Criteria: Phase I 1. CNS infiltration 2. Impaired cardiac function, including any one of the followings. - LVEF <45% as determined by MUGA scan or echocardiogram - Clinically significant resting bradycardia 3. Severe GI disease that may cause drug absorption problem of study drug 4. Use of therapeutic Warfarin 5. Acute or chronic liver or renal disease 6. Other concurrent severe and/or uncontrolled medical conditions 7. Treatment with any hematopoietic colony-stimulating growth factors =1 week prior to starting study drug. 8. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval 9. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy = 1 week 10. Patients who have received Nilotinib and Dasatinib =4 weeks prior to starting study drug. 11. Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy 12. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control. 13. Patients not to agree using birth control during the study and for up 3 months following study completion. 15. HIV infection Phase II 1. Blast phase CML 2. CNS infiltration 3. Impaired cardiac function, including any one of the following - LVEF< 45% as determined by MUGA scan or echocardiogram - Use of Cardiac pacemaker - ST depression > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads - Congenital long QT syndrome - History of, or presence of significant ventricular or atrial tachyarrhythmias - Clinically significant resting bradycardia - QTcF> 480 msec on screening ECG - Right bundle branch block + left anterior hemiblock, Bifascicular block - Angina pectoris 4. Severe GI disease that may cause drug absorption problem of study 5. Use of therapeutic Warfarin 6. Acute or chronic liver or renal disease 7. Other concurrent severe and/or uncontrolled medical conditions 8. Treatment with any hematopoietic colony-stimulating growth factors =1 week prior to starting study drug. 9. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval 10. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy = 1 week 11. Patients who have received wide field radiotherapy =4 weeks prior to starting study drug. 12. Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy 13. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control |
Country | Name | City | State |
---|---|---|---|
India | Local institution | Mumbai | Maharashtra |
India | Local institution | Mumbai | Mazagaon |
Korea, Republic of | Local institution | Anyang-si | Dongan-gu |
Korea, Republic of | Local institution | Busan | Seo-gu |
Korea, Republic of | Local institution | Daegu | Buk-gu |
Korea, Republic of | Local institution | Hwasun | Hwasun-eup |
Korea, Republic of | Local institution | Jeonju | Deokjin-gu |
Korea, Republic of | Local institution | Seoul | Jongro-ku |
Korea, Republic of | Seoul St. Mary's hospital | Seoul | Seocho-gu |
Korea, Republic of | Local institution | Suwon | Yeongtong-gu |
Korea, Republic of | Local institution | Ulsan | Dong-gu |
Thailand | Local institution | Bangkok | Phyathai |
Lead Sponsor | Collaborator |
---|---|
Il-Yang Pharm. Co., Ltd. |
India, Korea, Republic of, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To investigate the Maximum Tolerated Dose(Phase 1) | Radotinib will be given orally twice daily. Dose will be increased until it reaches MTD or the blood concentration of Radotinib stops rising | 12 month | |
Primary | Rate of Complete hematologic response(CHR)(Phase 2) | Main parameters for response assessment in the chronic and accelerated phases include Major Hematologic Responses (MR; No Evidence of Leukemia or NEL + Complete Hematologic Response or CHR) lasting for 4 weeks and at least one major cytogenetic response (MCyR) | 12 months | |
Secondary | To investigate the Dose Limiting Toxicity(Phase 1) | The initial cohort will include 3 subjects who will receive 100mg Radotinib daily. If DLT is observed in one of the 3 subjects, the same dose will be given to 3 more subjects to evaluate safety. | 12 months | |
Secondary | Rate of complete Cytogenetic Response(CCyR)(Phase 2) | Cytogenetic response rate will be calculated as the percentage of Ph+ bone marrow metaphases as follows at least 20 bone marrow metaphases should be analyzed. | 12 months | |
Secondary | Adverse events(Phase 1& Phase 2) | All adverse events recorded during the study will be itemized and summarized. Severity, relation to the study medication, and seriousness will be summarized for each adverse event. | 12 months | |
Secondary | Progression-free survival or PFS | It is defined as the duration from the first day of administration to the earliest day of disease progression or death for certain causes. In subjects who have shown response, disease progression is defined as loss of MCyR. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |